Search This Blog

Friday, June 26, 2026

FDA accepts Replimune resubmitted BLA for RP1 plus nivolumab in advanced melanoma

 

FDA accepts Replimune resubmitted BLA for RP1 plus nivolumab in advanced melanoma as a complete Class 1 response, sets Aug 2 2026 action date

  • FDA plans an advisory committee meeting in late July to review the RP1 BLA resubmission.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)